NexImmune, Inc.

NEXI

US65344D2080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.41 ^USD	+4.60%		+3.33%	+53.60%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

NexImmune, Inc.(NasdaqGM:NEXI) dropped from S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about NexImmune, Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
NexImmune, Inc. Announces CFO Changes	Apr. 05	CI
NexImmune, Inc. Announces Executive Changes	Apr. 05	CI
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Top Premarket Decliners	Jan. 04	MT
Top Premarket Decliners	Dec. 04	MT
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	Dec. 01	MT
Top Premarket Gainers	Dec. 01	MT
Investors Look Ahead to Powell Speech as US Futures Trend Lower Friday	Dec. 01	MT
North American Morning Briefing : Stocks Futures -2-	Nov. 20	DJ
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Top Premarket Decliners	Nov. 06	MT
Top Premarket Decliners	Nov. 03	MT
NexImmune Extends Partnership With Yale, JDRF for Type 1 Diabetes	23-10-24	MT
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	23-10-24	CI
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-18	MT
Sector Update: Health Care Stocks Sliding Wednesday Afternoon	23-10-18	MT
NexImmune Implements 1-for-25 Reverse Stock Split	23-10-18	MT
NexImmune Cutting Over Half of Workforce to Fund Development of Novel Therapeutic Candidates	23-08-31	MT
NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023	23-08-31	CI
NexImmune, Inc. Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	23-08-31	CI
NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023	23-08-31	CI
NexImmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
NEXIMMUNE, INC.	+53.60%	4.68M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.73%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.03%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs

NexImmune, Inc.

Equities

NEXI

US65344D2080

Biotechnology & Medical Research

NexImmune, Inc.(NasdaqGM:NEXI) dropped from S&P Global BMI Index

Latest news about NexImmune, Inc.

Chart NexImmune, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs